Novel Strategy for Synchronous Multiple Primary Lung Cancer Displaying Unique Molecular Profiles.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 26777970.
- Also identified by DOI 10.1016/j.athoracsur.2015.06.042.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report a rare case of multiple primary lung tumors displaying heterogeneous EGFR and KRAS molecular profiles, in which the patient underwent surgical resection of the gefitinib-insensitive peripheral lesion and continued gefitinib treatment for the gefitinib-sensitive bilateral multiple ground-glass opacity (GGO) lesions. The patient achieved complete remission and has been free of disease for 1.5 years. To the best of our knowledge, this novel strategy has not been previously reported. We consider our strategy to be safe and effective, and it appears to be a promising therapeutic approach for synchronous multiple primary lung cancer (SMPLC).
Medical subject headings
- Genes, erbB-1
- Lung Neoplasms
- Mutation
- Neoplasms, Multiple Primary
- Proto-Oncogene Proteins p21(ras)